

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/975,350	10/11/2001	Martin J. Jacobs	CP215	9510
27573 CEPHALON, 1	7590 05/02/2007	,	EXAMINER :	
41 MOORES ROAD		FUBARA, BLESSING M		
PO BOX 4011 FRAZER, PA			ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DÉLIVERY MODE
			05/02/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(a)			
		Application No.	Applicant(s)			
Office Action Summer		09/975,350	JACOBS ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Blessing M. Fubara	1618			
 Period for	The MAILING DATE of this communication app Reply	ears on the cover sheet with the c	orrespondence address			
WHICH - Extensi after SI - If NO pi - Failure Any rep	RTENED STATUTORY PERIOD FOR REPLY IEVER IS LONGER, FROM THE MAILING DA ons of time may be available under the provisions of 37 CFR 1.13 X (6) MONTHS from the mailing date of this communication. eriod for reply is specified above, the maximum statutory period w to reply within the set or extended period for reply will, by statute, bly received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	J. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1) 🛛 F	Responsive to communication(s) filed on 24 Ja	nuary 2007.				
·	_					
3)□ S	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
С	losed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.			
Dispositio	n of Claims					
5)□ C 6)□ C 7)□ C	Claim(s) <u>1,3,4,8-50,55-61 and 63-68</u> is/are penda) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1, 3, 4, 8-50, 55-61 and 63-68</u> are sub	vn from consideration.	requirement.			
Application	n Papers					
·	ne specification is objected to by the Examine					
	ne drawing(s) filed on is/are: a) acce					
	pplicant may not request that any objection to the o		` '			
	eplacement drawing sheet(s) including the correctine oath or declaration is objected to by the Ex		• • • • • • • • • • • • • • • • • • • •			
Priority un	der 35 U.S.C. § 119					
a) 1 2 3	cknowledgment is made of a claim for foreign All b) Some * c) None of: Certified copies of the priority documents Certified copies of the priority documents Copies of the certified copies of the prior application from the International Bureau e the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s	s) of References Cited (PTO-892)	4) Interview Summary	(PTO_413)			
2) Notice of 3) Informa	of References Cited (PTO-092) of Draftsperson's Patent Drawing Review (PTO-948) tion Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	Paper No(s)/Mail Da				

DETAILED ACTION

Examiner acknowledges receipt of request for continued examination, amendment and remarks, all filed 1/24/07. New claims 66-68 are added. Claims 2, 51 and 62 are canceled. Claims 1, 3, 4, 8-38, 41, 42, 44-50, 55, 57-59 and 63-65 are amended. Claims 1, 3, 4, 8-50, 55-61 and 63-68 are pending.

Upon further consideration, the invention filed at RCE has more than one invention; one invention were the modafinil is in a non-aqueous solution; one where and aqueous solution of modafinil is prepared and another in which a disease or disorder is treated with non-aqueous solution of modafinil. Therefore, a restriction requirement detailed below is required.

Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 3, 4, 8—34, 45-50, 55, 56, 59, 63, 66-68, drawn to non-aqueous modafinil solution, classified in class 514, subclass 615.
 - II. Claims 36-40 and 57, drawn to method of preparing aqueous solution of modafinil, classified in class 424, subclass 400.
 - III. Claims 41-44, 58, 60, 61, 64 and 65, drawn to method of treating disease or disorder, classified in class 424, subclass 489.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be

made by another and materially different process (MPEP § 806.05(f)). In the instant case the product of group I differs from the product made by Group II.

- 3. Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the product formed by Group II can be used in materially different process.
- 4. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art due to their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

5. Election:

If applicant elects Group I applicant must further elect soft or hard gelatin capsule.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, modafinil solution is generic for Group I.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Blessing Fubara Affred Patent Examine

Tech. Center 1600